Physician profile
Roy Escobar
NPI 1376120030
$3,322.09
in general payments reported to CMS, 2019-2025
27 companies · $1,550 in 2025
The $1,550 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $743 · 2024: $1,029 · 2025: $1,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $968.35 | 2025 | Solitaire X, Pipeline, Axium Primetm |
| Abbvie INC. | $295.65 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $261.56 | 2024 | Ingrezza |
| Jazz Pharmaceuticals INC. | $187.62 | 2024 | |
| Stryker Corporation | $165.85 | 2023 | |
| Emd Serono, INC. | $146.23 | 2023-2024 | Mavenclad |
| Genentech USA, INC. | $135.79 | 2023-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $132.74 | 2024-2025 | |
| Sk Life Science, INC. | $118.04 | 2023-2024 | Xcopri |
| Biogen, INC. | $98.62 | 2024-2025 | Tysabri, Vumerity |
| Takeda Pharmaceuticals U.S.A., INC. | $96.74 | 2023-2025 | Hyqvia |
| Ucb, INC. | $90.68 | 2023-2024 | Briviact, Rystiggo |
| Lundbeck LLC | $85.03 | 2024-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $84.48 | 2023-2025 | Ultomiris |
| Tg Therapeutics, INC. | $74.63 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $44.66 | 2024 | Dysport |
| Otsuka America Pharmaceutical, INC. | $42.54 | 2024-2025 | Nuedexta, Rexulti |
| Vanda Pharmaceuticals INC. | $40.76 | 2025 | Ponvory |
| Pfizer INC. | $36.11 | 2023 | |
| Immedica Pharma US, INC. | $35.28 | 2023 | |
| Ani Pharmaceuticals, INC. | $34.96 | 2025 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $34.28 | 2025 | Inbrija |
| Lilly USA, LLC | $33.27 | 2024-2025 | Amyvid, Kisunla |
| Livanova USA, INC. | $26.20 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| E.R. Squibb & Sons, L.L.C. | $18.59 | 2024 | Opdivo |
| Octapharma USA, INC. | $18.17 | 2024 | Panzyga |
| Azurity Pharmaceuticals, INC. | $15.26 | 2025 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.